A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
May 16th, 2020
Described is a protocol to establish a Doxorubicin-induced dilated cardiomyopathy (DCM) model in mice via long-term intraperitoneal injection of Doxorubicin.
How a Doxorubicin-induced dilated cardiomyopathy model is a stable, reliable, and economical.This method will contribute to varying the pathogenesis on dilated cardiomyopathy and to exploring new drugs.Dissolve doxorubicin hydrochloride in sterilized water at a concentration of one milligram per milliliter.Vortex the solution and store it at four degrees Celsius.Maintain eight to 10-week-old mice in pathogen-free mouse cages with a 12-hour light-dark cycle at a constant temperature of 23 degrees Celsius.And provide as much food and water as needed.Before beginning treatment, randomize mice into a control group and a dox group.For mice in the dox group, use one milliliter sterilized syringes to inject the dox solution intraperitoneally.Administer a dose of five milligrams per kilogram of body weight intraperitoneally once per week.Perform the injection in the lower left or right quadrant of the abdomen, taking care of to avoid the urinary bladder and other abdominal organs.For four weeks measure the body weight of the mice weekly and adjust the injection dose accordingly each week.After confirming anesthesia, use depilatory cream to carefully remove the chest fur.After performing echocardiography, use the M-mode tracings to measure the average LV end
View the full transcript and gain access to thousands of scientific videos
Overview
This article describes a protocol for establishing a Doxorubicin-induced dilated cardiomyopathy (DCM) model in mice. The model is created through long-term intraperitoneal injection of Doxorubicin, which is crucial for studying heart disease.
Key Study Components
Area of Science
- Cardiology
- Pharmacology
- Animal Models
Background
- Doxorubicin is a chemotherapeutic agent known to induce cardiotoxicity.
- Dilated cardiomyopathy is a significant complication associated with cancer treatment.
- Animal models are essential for understanding the mechanisms of DCM.
- This protocol aims to standardize the method for inducing DCM in mice.
Purpose of Study
- To establish a reliable DCM model in mice.
- To facilitate research on the pathophysiology of DCM.
- To evaluate potential therapeutic interventions for DCM.
Methods Used
- Long-term intraperitoneal injection of Doxorubicin.
- Monitoring of cardiac function and morphology.
- Assessment of biochemical markers of heart failure.
- Use of echocardiography for functional analysis.
Main Results
- Successful induction of DCM in the mouse model.
- Characterization of cardiac dysfunction and structural changes.
- Identification of biomarkers associated with DCM progression.
- Potential for further studies on therapeutic strategies.
Conclusions
- The Doxorubicin-induced DCM model is effective for research.
- This model can help in understanding the mechanisms of cardiotoxicity.
- Future studies can leverage this model for drug testing and intervention strategies.
Frequently Asked Questions
Executive Industry Relevance
Establishing a reliable in vivo model of doxorubicin-induced dilated cardiomyopathy enables mechanistic de-risking of cardiotoxicity in oncology drug development. This model supports target validation and preclinical safety assessment by recapitulating key pathophysiological features of chemotherapy-associated heart failure. It provides a disease-relevant system for evaluating cardioprotective strategies and improving go/no-go decisions in early discovery.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of doxorubicin-induced cardiotoxicity pathways involving oxidative stress, inflammation, and apoptosis.
- Operational Value: Offers a stable and economical model for consistent target engagement and mechanism-of-action studies.
Screening & Assay Development
- Scientific Value: Generates quantifiable cardiac dysfunction readouts via echocardiography for compound screening.
- Operational Value: Supports assay standardization through longitudinal monitoring of LV dimensions and fractional shortening.
Translational & Preclinical Research
- Scientific Value: Models disease progression from asymptomatic dysfunction to overt heart failure for biomarker discovery.
- Operational Value: Facilitates preclinical evaluation of therapeutic interventions with translational continuity to clinical cardiotoxicity.
Pipeline & Workflow Integration
The model fits within the discovery-to-preclinical continuum, enabling early assessment of cardiovascular liability in oncology candidates.
- Discovery Biology: Supports hypothesis testing of doxorubicin’s mechanistic pathways in cardiomyocyte injury.
- Screening: Delivers reproducible functional endpoints for compound library screening and lead optimization.
- Analytics: Provides quantitative M-mode echocardiography measurements for longitudinal tracking of cardiac structure and function.
- Translational Research: Mirrors clinical doxorubicin-induced DCM, enabling preclinical validation of cardioprotective agents.
- Enterprise Reuse: Serves as a reusable platform for cross-project cardiotoxicity screening in oncology portfolios.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in cardiovascular safety assessment by modeling human-relevant cardiotoxicity.
- Operational Value: Ensures reproducibility through standardized dosing, anesthesia, and imaging protocols.
- Strategic Value: Reduces late-stage attrition by enabling early identification of cardiac liability in drug candidates.
- Portfolio Impact: Informs risk-adjusted prioritization of oncology compounds based on cardiovascular safety profiles.
Implementation Considerations
- Requires expertise in rodent handling, intraperitoneal injection, and echocardiography.
- Depends on access to high-frequency ultrasound systems and analytical software for cardiac measurements.
- Necessitates cross-functional alignment between pharmacology, cardiology, and pathology teams for data interpretation.
- Involves adaptation considerations for different mouse strains, ages, and dosing regimens to model variable susceptibility.
- Limited by the need for longitudinal monitoring over four weeks, which impacts study timelines and resource planning.
